Tongyue

Dr. Tong Yue has been dedicated to the research and development of biopharmaceuticals, particularly the application of protein and peptide drugs in metabolic diseases. In recent years, Dr. Tong’s work has mainly focused on the quality research of biopharmaceuticals.

[1] Yue Tong (Co-first author), Sai Xu, Lili Huang*, Chen Chen*. Obesity and insulin resistance: Pathophysiology and treatment. Drug Discovery Today. 2022,27(3): 822-830.

[2] Lei Hu, Zhenzhen Shan, Feng Wang, Xiangdong Gao*, Yue Tong*. Vascular endothelial growth factor B exerts lipid-lowering effect by activating AMPK via VEGFR1. Life Sciences. 2021,276:119401.

[3] Yue Tong (Co-first author), Yu Zhang, Zhenzhen Shan, Yueming Xu, Xiangdong Gao*, Wenbing Yao*. Improving High-fat Diet-induced Obesity and Fatty Liver by Adipose Tissue Targeted Delivery of Vascular Endothelial Growth Factor-B. Life Sciences. 2020,253:117677.

[4] Yue Tong (Co-first author), Shengwei Zhong, Zhenzhen Shan, Wenbing Yao*, Hong Tian*. A novel human anti-BAFF neutralizing monoclonal antibody derived from in vitro immunization. Biomed Pharmacother. 2019,119:109430.

Yue Tong (Co-first author), Xu Fang, Hong Tian, Shengwei Zhong, Liang Jin, Xiangdong Gao*, Wenbing Yao*. De novo generation of specific human IgGs by in vitro immunization using autologous proteins containing immunogenic p-nitrophenylalanine. mAbs, 2019,11(2):401- 410

analytical method development and validation

National first-class undergraduate courses (2/5)